Predictive biomarkers of breast ductal carcinoma in situ may underestimate the risk of recurrence due to de novo ipsilateral breast carcinoma development
Tanjina Kader,Maia Zethoven,Sakshi Mahale,Hugo Saunders,Lauren Tjoeka,Rebecca Lehmann,Madawa Jayawardane,Jia-Min Pang,Dorothea Lesche,Neeha Rajan,Timothy Semple,Jue Er Amanda Lee,Richard Lupat,David J Byrne,Siobhan Hughes,Hoa Nguyen,Siqi Lai,Maree Pechlivanis,Olivia Craig,Lisa Devereux,Eloise House,Sureshni I Jayasinghe,Tom L Kaufmann,Roland F Schwarz,Andrew R Green,Islam Miligy,Margaret Cummings,Sunil Lakhani,Ian G Campbell,Emad Rakha,Stephen B Fox,G Bruce Mann,Kylie L Gorringe
DOI: https://doi.org/10.1101/2024.05.19.594731
2024-05-21
Abstract:Purpose: Development of ipsilateral breast carcinoma following a diagnosis of breast ductal carcinoma in situ (DCIS) has been assumed to represent recurrence of the primary tumour. However, this may not be the case and it is important to know how often recurrences are new primary tumours to ensure appropriate individualised therapy.
Experimental Design: Ipsilateral primary-recurrence pairs (n=78) were sequenced to test their clonal relatedness. Shared genetic events were identified from whole exome sequencing (n=54 pairs) using haplotype-specific copy number and phylogenetic analysis. The remaining pairs were sequenced by a targeted panel or low-coverage whole genome sequencing. We included 32 non-recurrent DCIS to compare the genetic profiles between recurrent and non-recurrent disease to develop a predictive biomarker.
Results: We found that 14% of DCIS recurrences were non-clonal, indicative of a new breast carcinoma. Four chromosomal changes (5q, 11q, 17q and 20q) and TP53 mutation were enriched in clonal primaries compared with non-recurrent DCIS (p<0.05, Fisher exact test). The prognostic value of TP53 was validated in an independent cohort using immunohistochemistry (HR=3.1; 95% CI 1.3-7.8). Non-clonal DCIS primaries had a very similar genetic profile to non-recurrent DCIS, suggesting this subset of cases would be identified as being at low risk of recurrence using tumour-intrinsic markers.
Conclusions: We have identified a substantial rate of new ipsilateral primary carcinomas after a diagnosis of DCIS. Our results suggest, as with invasive breast cancer, that if a recurrent tumour with an independent origin occurs, then the patient is at a high risk through the environment, the breast microenvironment and/or has a genetic predisposition. Importantly, the frequency of new primaries will influence the interpretation of findings in DCIS biomarker discovery studies as the true recurrence rate will be incorrect, affecting these efforts.
Biology